Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company’s clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Metrics to compare | BTTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBTTXPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −1.9x | −0.5x | |
PEG Ratio | 0.00 | 0.01 | 0.00 | |
Price/Book | 0.0x | 1.6x | 2.6x | |
Price / LTM Sales | 0.0x | 2.7x | 3.3x | |
Upside (Analyst Target) | 0.0% | 30.5% | 43.5% | |
Fair Value Upside | Unlock | 16.1% | 6.8% | Unlock |